<DOC>
	<DOCNO>NCT01710852</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment ISIS CRP Rx reduce AF ( Atrial Fibrillation ) burden ( percentage time spend AF ) subject paroxysmal AF</brief_summary>
	<brief_title>Antiarrhythmic Symptomatic Effect ISIS CRP Rx Targeting CRP Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Male female ; age 18 year Dual chamber permanent pacemaker implant Confirmed diagnosis paroxysmal atrial fibrillation AF burden 1 50 % , derive pacemaker diagnostic algorithm Able pacemaker antiarrhythmic algorithm turn duration study Able discontinue Class I III antiarrhythmic medication duration study Therapeutically anticoagulated warfarin dabigatran , anticipate duration study High sensitivity CReactive Protein ( hsCRP ) 2 10 mg/L ( inclusive ) Clinically significant abnormality medical history , physical examination , screen laboratory result would render subject unsuitable inclusion NYHA class III/IV heart failure Impaired leave ventricular function le 45 % determine echocardiography within 3 month screen Moderate great mitral regurgitation assess echocardiography within 3 month screen Permanent AF Continuous Amiodarone therapy within 90 day prior Study Day 1 Treatment another Study Drug , biological agent , device within onemonth screening , five halflives study agent , whichever long Use systemic corticosteroid antiinflammatory medication include nonsteroidal antiinflammatory drug ( NSAIDs ) Use statins , ACE inhibitor ATreceptor antagonists unless stable regimen least 3 month prior dose remain stable regimen duration study Uncontrolled hypertension ( BP &gt; 160/100 ) Current expect use anticoagulant apart warfarin dabigatran</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>AF</keyword>
</DOC>